Our previous studies demonstrated that at the advanced stage of HF in Tgαq*44 mice, when ejection fraction (EF) was significantly decreased and cardiac reserve was lost (in 12-month -old mice) (Tyrankiewicz et al., 2018), only modest improvement in cardiac performance was possible following 2 months of ACE-I treatment combined with aldosterone receptor antagonist mostly related to attenuation of LV remodeling and preservation of functional reserve, without any significant effects on myocardial function parameters at rest (Wozniak et al., 2013). This evidence concerns the gene NR3C2 and hydrops fetalis.